Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | PKLR | P30613 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30843261 | 1.00 | MEN1 (0.39) | MEN1KMT2ANPBWR1ADORA1ADORA2A | |
| SCHEMBL21458330 | 0.89 | ALDH1A1 (0.44) | MEN1KMT2ANPBWR1ERCC5FEN1 | |
| SCHEMBL30843256 | 0.89 | ALDH1A1 (0.44) | MEN1KMT2ANPBWR1ERCC5FEN1 | |
| SCHEMBL26602905 | 0.83 | MEN1 (0.43) | MEN1KMT2ANPBWR1ADORA1ADORA2A | |
| SCHEMBL21458331 | 0.83 | MEN1 (0.43) | MEN1KMT2ANPBWR1ADORA1ADORA2A | |
| SCHEMBL30843282 | 0.80 | NPBWR1 (0.40) | MEN1KMT2ANPBWR1ERCC5FEN1 | |
| SCHEMBL21458245 | 0.80 | NPBWR1 (0.40) | MEN1KMT2ANPBWR1ERCC5FEN1 | |
| SCHEMBL24774583 | 0.79 | MEN1 (0.40) | MEN1KMT2ANPBWR1ADORA1ADORA2A | |
| SCHEMBL28450982 | 0.78 | SMN1; SMN2 (0.44) | MEN1KMT2ANPBWR1ADORA1ADORA2A | |
| SCHEMBL24774860 | 0.78 | MEN1 (0.39) | MEN1KMT2ANPBWR1ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-3781550-B1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS INC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| CN-112313208-B | Bicyclic carboxamides and methods of use thereof | 泰普斯特医疗公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11472789-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-112313208-A | Bicyclic carboxamides and methods of use thereof | 泰普斯特医疗公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
| US-20240150316-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
| US-11472789-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
| US-20250353829-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
| US-12215093-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.